

Wassim Abida

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6705418/publications.pdf>

Version: 2024-02-01

47
papers

12,632
citations

186265

28
h-index

197818

49
g-index

50
all docs

50
docs citations

50
times ranked

17232
citing authors

#	ARTICLE	IF	CITATIONS
1	Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. <i>Clinical Cancer Research</i> , 2022, 28, 318-326.	7.0	28
2	Inherited TP53 Variants and Risk of Prostate Cancer. <i>European Urology</i> , 2022, 81, 243-250.	1.9	40
3	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	28.9	223
4	Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Cancer Management and Research</i> , 2022, Volume 14, 673-686.	1.9	4
5	AKT mutant allele-specific activation dictates pharmacologic sensitivities. <i>Nature Communications</i> , 2022, 13, 2111.	12.8	10
6	Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality. <i>Prostate</i> , 2022, , .	2.3	3
7	Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. <i>Science</i> , 2022, 376, .	12.6	75
8	The Impact of PIK3R1 Mutations and Insulinâ€“PI3Kâ€“Glycolytic Pathway Regulation in Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3603-3617.	7.0	7
9	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. <i>Genome Medicine</i> , 2021, 13, 96.	8.2	26
10	BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. <i>Clinical Cancer Research</i> , 2021, 27, 4923-4936.	7.0	33
11	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. <i>Nature Communications</i> , 2021, 12, 3770.	12.8	68
12	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2021, 39, 2698-2709.	1.6	83
13	Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. <i>Clinical Cancer Research</i> , 2021, 27, 6677-6686.	7.0	12
14	Attenuation of SRC Kinase Activity Augments PARP Inhibitorâ€“mediated Synthetic Lethality in <i>BRCA2</i> -altered Prostate Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 1792-1806.	7.0	13
15	Significance of <i>BRCA2</i> and <i>RB1</i> Co-loss in Aggressive Prostate Cancer Progression. <i>Clinical Cancer Research</i> , 2020, 26, 2047-2064.	7.0	77
16	Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1167-1179.	3.0	28
17	Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. <i>Cancer Cell</i> , 2020, 38, 279-296.e9.	16.8	135
18	Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a <i>BRCA1</i> or <i>BRCA2</i> Gene Alteration. <i>Journal of Clinical Oncology</i> , 2020, 38, 3763-3772.	1.6	448

#	ARTICLE	IF	CITATIONS
19	Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3230-3238.	7.0	112
20	Somatic Tissue Engineering in Mouse Models Reveals an Actionable Role for WNT Pathway Alterations in Prostate Cancer Metastasis. <i>Cancer Discovery</i> , 2020, 10, 1038-1057.	9.4	37
21	Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 507-516.	3.9	10
22	Regenerative potential of prostate luminal cells revealed by single-cell analysis. <i>Science</i> , 2020, 368, 497-505.	12.6	165
23	Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation. <i>Cancer Cell</i> , 2020, 37, 584-598.e11.	16.8	96
24	Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. <i>European Urology</i> , 2020, 78, 671-679.	1.9	72
25	Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. <i>JCO Precision Oncology</i> , 2020, 4, 355-366.	3.0	93
26	Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. <i>Clinical Cancer Research</i> , 2020, 26, 2487-2496.	7.0	273
27	Tumour lineage shapes BRCA-mediated phenotypes. <i>Nature</i> , 2019, 571, 576-579.	27.8	295
28	Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>European Urology Oncology</i> , 2019, 2, 605-616.	5.4	30
29	Genomic correlates of clinical outcome in advanced prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 11428-11436.	7.1	839
30	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. <i>JAMA Oncology</i> , 2019, 5, 471.	7.1	426
31	Low Expression of the Androgen-Induced Tumor Suppressor Gene <i>PLZF</i> and Lethal Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 707-714.	2.5	11
32	The long tail of oncogenic drivers in prostate cancer. <i>Nature Genetics</i> , 2018, 50, 645-651.	21.4	601
33	Targeting DNA Repair in Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1017-1019.	1.6	4
34	Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. <i>ELife</i> , 2018, 7, .	6.0	217
35	<i>SOX2</i> promotes lineage plasticity and antiandrogen resistance in <i>TP53</i> - and <i>RB1</i> -deficient prostate cancer. <i>Science</i> , 2017, 355, 84-88.	12.6	759
36	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	30.7	2,473

#	ARTICLE	IF	CITATIONS
37	Prognostic and Predictive Value of a Breast Cancer Expression Signature in Localized Prostate Cancer. <i>JAMA Oncology</i> , 2017, 3, 1673.	7.1	1
38	ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis. <i>Nature</i> , 2017, 546, 671-675.	27.8	70
39	A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. <i>Investigational New Drugs</i> , 2017, 35, 742-750.	2.6	10
40	Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffeyâ€¦Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2017, 77, 1478-1488.	2.3	7
41	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 825.	7.4	366
42	Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. <i>ELife</i> , 2017, 6, .	6.0	154
43	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	3.0	286
44	Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma. <i>Bladder Cancer</i> , 2016, 2, 111-117.	0.4	8
45	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 443-453.	27.0	1,205
46	Integrative Clinical Genomics of Advanced Prostate Cancer. <i>Cell</i> , 2015, 161, 1215-1228.	28.9	2,660
47	First-Line Treatment and Prognostic Factors of Metastatic Bladder Cancer for Platinum-Eligible Patients. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 319-328.	2.2	21